This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Sarepta Therapeutics: A High-Octane Options Trade

Stocks in this article: SRPT

NEW YORK ( TheStreet) -- Sarepta Therapeutics (SRPT) is slated to announce key data on the company's Duchenne muscular dystrophy (DMD) drug candidate eteplirsen at the International Congress of the World Muscle Society in a late-breaker session on October 13. Recent favorable press, momentum from a string of positive results, and speculation about the possibility of accelerated approval have catapulted the stock from $4 to over $16 per share over the past several weeks. On Sept. 4, Sarepta announced a $40 million at-the-market equity offering; shares subsequently sold off to around $13.

The October options, the expiration nearest to the late breaker session, currently imply an up or down move of around $7 per share (Sarepta could rise to $20 or fall to $6.) Traders wishing to speculate on an upside move face a high-risk proposition by buying equity and holding into the eteplirsen results. Bad data could potentially result in an immediate 50% loss or more on one's initial investment. An alternative (and I believe preferred) approach is to use trade Sarepta and the upcoming eteplirsen data announcement with options.

Try this Sarepta options trade if you want to speculate on the long side:

Sell (10) OCT 7.50 strike Puts at 0.90 = $(900)
Buy 20 OCT 15.0 strike Calls at 2.95 = $5,900
Sell (40) OCT 20.0 strike Calls at 1.75 = $(7,000)
Buy 20 OCT 25.0 strike Calls at 1.05 = $2,100
Initial Trade P&L = $100 Debit

From an execution perspective, this trade should be placed in two separate orders: First the Call Butterfly and then the Put Sale. Trying to complete this trade in one order may not be possible.

This is a very wide strike Call Butterfly near fully financed by a deep out-of-the-money sold Put. The trade results in an initial P&L debit of $100, the initial cost of the trade excluding commissions, and offers the potential to earn up to 100 times on that money. Yes, that's not a typo, the upside on this trade is 100 times the initial investment -- high octane indeed!

At Sarepta shares prices between $15 and $25, the trade is profitable with a maximum profit of nearly $10,000 at $20 per share, which is in-line with the implied upside movement and recent analyst price targets. See the P&L diagram below.

With Saretpa shares between $7.50 and $15, the trade results in a small loss equal to the initial debit, or $100. As we sold a Put to finance the trade, the key risk of this structure is to the downside. Assuming the $7 move in the shares implied by October options is accurate, a downside price for Sarepa shares on negative data could be $6. Under this scenario, losses from the trade I've outlined would be around $1,600. (Please note this is only an estimate and losses could be much bigger.)

Pelz has no position in Sarepta as of the publication this article.

To learn more about using options to trade biotech catalysts, check out Tony Pelz's book, The Biotech Trader Handbook.

Tony Pelz was a trader on a major European bank's proprietary trading desk, responsible for a portfolio with limits of more than $200 million. Prior to proprietary trading, Pelz worked with several global investment banks in roles ranging from corporate finance, M&A to credit and business development. He is author of The Biotech Trader Handbook, 2nd Edition, co-founder of the small-cap biotech research and trading site Chimera Research Group and operator of PelzOptions.com. Pelz currently resides in Denver, Colorado where he trades for his own account.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,786.53 +67.53 0.38%
S&P 500 2,060.54 +7.79 0.38%
NASDAQ 4,709.6230 +7.7560 0.16%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs